Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 7
  • Print publication year: 2010
  • Online publication date: February 2010

Chapter 22 - Inflammatory myopathies

from Section 3B - Description of muscle disease – specific diseases

References

1. M. C. Dalakas, Polymyositis and Dermatomyositis. (Boston, MA: Butterworths, 1988.)
2. M. C. Dalakas, Polymyositis, dermatomyositis, and inclusion-body myositis. N. Engl. J. Med. 325 (1991), 1487–1498.
3. M. C. Dalakas, R. Hohlfeld, Polymyositis and dermatomyositis. Lancet 362:9388 (2003), 971–982.
4. G. Karpati, S. Carpenter, Pathology of the inflammatory myopathies. Baillière's Clin. Neurol. 2 (1993), 527–556.
5. A. G. Engel, R. Hohlfeld, B. Q. Banker, The polymyositis and dermatomyositis syndrome. In Myology, eds. A. G. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 2006), pp. 1335–1383.
6. G. Karpati, G. S. Currie, The inflammatory myopathies. In Disorders of Voluntary Muscle, eds. J. Walton, G. Karpati, D. Hilton-Jones. (Edinburgh: Churchill-Livingston, 1994), pp. 619–646.
7. F. L. Mastaglia, M. J. Garlepp, B. A. Phillips, P. J. Zilko, Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 27:4 (2003), 407–425.
8. C. Otero, I. Illa, M. C. Dalakas, Is there dermatomyositis (DM) without myositis?Neurology 42 (1992), 388S.
9. P. A. Hertzmann, W. L. Blevins, J. Mayer, B. Greenfield, M. Ting, G. J. Gleich, Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N. Engl. J. Med. 322 (1990), 869–873.
10. I. Illa, S. Dinsmore, M. C. Dalakas, Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by l tryptophan. Hum. Pathol. 24 (1993), 702–709.
11. R. Temiz, C. C. Weihl, A. Pestronk, Inflammatory myopathies with mitochondrial pathology and protein aggregates. J. Neurol. Sci. 278:1-2 (2009), 25–29.
12. G. Karpati, S. Carpenter, Evolving concepts about inclusion body myositis. In Actualités Neuromusculaires: Acquisition Récentes, eds. G. Serratrice, J. F. Pellesier, J. Pouget, et al. (Paris: Exp. Scient. Française, 1993), pp. 93–98.
13. E. A. Sekul, M. C. Dalakas, Inclusion body myositis: new concepts. Semin. Neurol. 13 (1993), 256–263.
14. R. C. Griggs, V. Askanas, S. DiMauro, et al., Inclusion body myositis and myopathies. Ann. Neurol. 38 (1995), 705–713.
15. S. Carpenter, Inclusion body myositis, a review. J. Neuropathol. Exp. Neurol. 55 (1996), 1105–1114.
16. G. Karpati, Inclusion body myositis – Status 1997. Neurologist 3 (1997), 201–208.
17. M. C. Dalakas, Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 66:2 (Suppl 1) (2006), S33–S38.
18. M. Needham, F. L. Mastaglia, Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 6:7 (2007), 620–631.
19. M. Needham, F. L. Mastaglia, Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul. Disord. 18:1 (2008), 6–16.
20. K. Sivakumar, M. C. Dalakas, The spectrum of familial inclusion body myopathies in 13 families and description of a quadriceps sparing phenotype in non-Iranian Jews. Neurology 47 (1996), 977–984.
21. K. Sivakumar, M. C. Dalakas, Inclusion body myositis and myopathies. Curr. Opin. Neurol. 10 (1997), 413–420.
22. Z. Argov, R. Yarom, ‘Rimmed vacuole myopathy’ sparing the quadriceps: a unique disorder in Iranian Jews. J. Neurol. Sci. 64 (1984), 33–43.
23. E. A. Sekul, C. Chow, M. C. Dalakas, Magnetic resonance imaging of the forearm as a diagnostic aid in patients with inclusion body myositis. Neurology 48 (1997), 863–866.
24. C. A. Luciano, M. C. Dalakas, A macro-EMG study in inclusion-body myositis: no evidence for a neurogenic component. Neurology 48 (1997), 29–33.
25. J. M. Schroder, M. Molnar, Mitochondrial abnormalities and peripheral neuropathy in inflammatory myopathy, especially inclusion body myositis. Mol. Cell. Biochem. 174 (1997), 277–282.
26. B. M. Koffman, M. Rugiero, M. C. Dalakas, Autoimmune diseases and autoantibodies associated with sporadic inclusion body myositis. Muscle Nerve 21 (1998), 115–117.
27. U. A. Badrising, G. M. Schreuder, M. J. Giphart, et al., Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 63:12 (2004), 2396–2398.
28. B. M. Koffman, K. Sivakumar, T. Simonis, D. Stroncek, M. C. Dalakas, HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J. Neuroimmunol. 84 (1998), 139–142.
29. K. Sivakumar, C. Semino-Mora, M. C. Dalakas, An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in 3 families. Brain 120 (1997), 653–661.
30. A. J. Cole, R. Kuzniecky, G. Karpati, S. Carpenter, E. Andermann, F. Andermann, Familial myopathy with changes resembling inclusion body myositis and periventricular leucoencephalopathy. Brain 111 (1988), 1025–1037.
31. R. Massa, B. Weller, G. Karpati, E. Shoubridge, S. Carpenter, Familial inclusion body myositis among Kurdish-Iranian Jews. Arch. Neurol. 48 (1991), 519–522.
32. I. Eisenberg, N. Avidan, T. Potikha, et al., The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat. Genet. 29:1 (2001), 83–87.
33. G. D. Watts, J. Wymer, M. J. Kovach, et al., Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36:4 (2004), 377–381.
34. A. Peng, B. M. Koffman, J. D. Malley, M. C. Dalakas, Disease progression in sporadic inclusion body myositis (s-IBM): observations in 78 patients. Neurology 55 (2000), 296–298.
35. K. Clawson, C. V. Oddis, Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-I antibody. Arthritis Rheum. 38 (1995), 1519–1523.
36. M. I. Schwarz, J. M. Sutarik, J. A. Nick, R. L. Leff, J. W. Emlen, R. M. Tuder, Pulmonary capillaritis and diffuse alveolar hemorrhage: a primary manifestation of polymyositis. Am. J. Respir. Crit. Care Med. 151 (1995), 2037–2040.
37. M. C. Dalakas, Calcifications in dermatomyositis. N. Engl. J. Med. 333 (1995), 978.
38. S. Carpenter, G. Karpati, The major inflammatory myopathies of unknown cause. Pathol. Ann. 16 (1981), 205–237.
39. A. G. Engel, B. Q. Banker, Myology. (New York: McGraw-Hill, 1986.)
40. S. Carpenter, G. Karpati, The pathological diagnosis of specific inflammatory myopathies. Brain Pathol. 2 (1992), 13–19.
41. F. Jerusalem, M. Rakusa, A. G. Engel, R. D. Macdonald, Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies. J. Neurol. Sci. 23 (1974), 391–401.
42. M. De Visser, A. M. Emslie-Smith, A. G. Engel, Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J. Neurol. Sci. 94 (1989), 181–192.
43. A. M. Emslie-Smith, A. G. Engel, Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27 (1990), 343–356.
44. J. T. Kissel, J. R. Mendell, K. W. Rammohan, Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314 (1986), 329.
45. J. T. Kissel, R. K. Halterman, K. W. Rammohan, J. R. Mendell, The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch. Neurol. 48 (1991), 26–30.
46. K. Arahata, A. G. Engel, Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibres invaded by T cells. Ann. Neurol. 16 (1984), 193–208.
47. K. Arahata, A. G. Engel, Monoclonal antibody analysis of mononuclear cells in myopathies III. Immunoelectron microscopy aspects of cell-mediated muscle fibre injury. Ann. Neurol. 19 (1986), 112–125.
48. B. P. Lotz, A. G. Engel, H. Nishino, J. C. Stevens, W. J. Litchy, Inclusion body myositis. Observations in 40 patients. Brain 112 (1989), 727–747.
49. V. Askanas, W. K. Engel, M. Bilak, R. B. Alvarez, D. J. Selkoe, Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain containing hyperphosphorylated tau. Am. J. Pathol. 144 (1994), 177–187.
50. V. Askanas, P. Serdaroglu, W. K. Engel, R. B. Alvarez, Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology 42 (1992), 460–461.
51. V. Askanas, W. K. Engel, R. B. Alvarez, G. G. Glenner, β-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Lancet 339 (1992), 560–561.
52. V. Askanas, W. K. Engel, R. B. Alvarez, Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer disease using fluorescence technique. Neurology 43 (1993), 1265–1267.
53. J. L. De Bleecker, B. B. Ertl, A. G. Engel, Patterns of abnormal parotein expression in target formations and unstructured cores. Neuromuscul. Disord. 6 (1996), 339–349.
54. C. Semino-Mora, M. C. Dalakas, Rimmed vacuoles with β-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum. Pathol. 29 (1998), 1128–1133.
55. J. R. Mendell, Z. Sahenk, T. Gales, L. Paul, Amyloid filaments in inclusion body myositis. Arch. Neurol. 48 (1991), 1229–1234.
56. J. D. Lünemann, J. Schmidt, D. Schmid, et al., Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann. Neurol. 61:5 (2007), 476–483.
57. J. Nalbantoglu, G. Karpati, S. Carpenter, Conspicuous accumulation of a single- stranded DNA binding protein in skeletal muscle fibres in inclusion body myositis. Am. J. Pathol. 144 (1994), 874–882.
58. S. A. Greenberg, J. L. Pinkus, A. A. Amato, Nuclear membrane proteins are present within rimmed vacuoles in inclusion body myositis. Muscle Nerve 34 (2006), 406–416.
59. R. Horvath, K. Fu, A. Genge, G. Karpati, E. A. Shoubridge, Characterization of the mitochondiral DNA abnormalities in the skeletal muscle of patients with inclusion body myositis. J. Neuropathol. Exp. Neurol. 57 (1998), 396–403.
60. G. Karpati, Y. Pouliot, S. Carpenter, Expression of immunoreactive major histocompatability complex products in human skeletal muscles. Ann. Neurol. 23 (1988), 64–72.
61. A. M. Emslie-Smith, K. Arahata, A. G. Engel, Major histocompatibility complex class I antigen expression, immunologicalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum. Pathol. 20 (1989), 224–231.
62. J. T. Kissel, K. L. Burrow, K. W. Rammohan for the CIDD Group, Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 41 (1991), 667–672.
63. M. Krahn, A. Lopez de Munain, et al., CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann. Neurol. 59:6 (2006), 905–911.
64. N. Chahin, A. G. Engel, Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:6 (2008), 418–424.
65. S. Carpenter, G. Karpati, S. Rothman, G. Walters, The childhood type of dermatomyositis. Neurology 26 (1976), 952–962.
66. J. N. Whitaker, W. K. Engel, Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N. Engl. J. Med. 286 (1972), 333–338.
67. M. Basta, M. C. Dalakas, High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94 (1994), 1729–1735.
68. M. C. Dalakas, Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat. Clin. Pract. Rheumatol. 4 (2006), 219–227.
69. M. C. Dalakas, Immunopathogenesis of inflammatory myopathies. Ann. Neurol. 37 (1995), 74–86.
70. D. P. Stein, M. C. Dalakas, Intercellular adhesion molecule-1 expression is upregulated in patients with dermatomyositis (DM). Ann. Neurol. 34 (1993), 268.
71. I. Lundberg, J. M. Brengman, A. G. Engel, Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne's dystrophy and non-weak controls. J. Neuroimmunol. 63 (1995), 9–16.
72. D. S. Tews, H. H. Goebel, Expression of cell adhesion molecules in inflammatory myopathies. J. Neuroimmunol. 59 (1995), 185–194.
73. D. S. Tews, H. H. Goebel, Cytokine expression profiles in idiopathic inflammatory myopathies. J. Neuropathol. Exp. Neurol. 55 (1996), 342–347.
74. J. L. De Paepe, B. De Bleecker, I. E. Vanwalleghem, J. M. Schröder, Differential expression of chemokines in inflammatory myopathies. Neurology 58:12 (2002), 1779–1785.
75. R. Raju, O. Vasconcelos, R. Granger, M. C. Dalakas, Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J. Euroimmunol 141:1–2 (2003), 125–131.
76. K. Amemiya, C. Semino-Mora, R. P. Granger, M. C. Dalakas, Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin. Immunol. 94:2 (2000), 99–104.
77. I. Illa, E. Gallardo, R. Gimeno, C. Serrano, I. Ferrer, C. Juárez, Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies. Am. J. Pathol. 151:1 (1997), 81–88.
78. J. Schmidt, et al., Interplay between inflammatory and degeneration-associated molecules in sporadic IBM. Brain 131 (2008), 1228–1240.
79. S. A. Greenberg, J. L. Pinkus, G. S. Pinkus, et al., Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57:5 (2005), 664–678.
80. R. Raju, M. C. Dalakas, Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128:Pt 8 (2005), 1887–1896.
81. S. A. Greenberg, Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 69:21 (2007), 2008–2019.
82. R. J. Walsh, S. W. Kong, Y. Yao, et al., Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56:11 (2007), 3784–3792.
83. Z. Tezak, E. P. Hoffman, J. L. Lutz, et al., Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel pathogenesis. J. Immunol. 168:8 (2002), 4154–4163.
84. R. L. Leff, L. A. Love, F. W. Miller, et al., Viruses in the idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 339 (1992), 1192–1195.
85. M. Leon-Monzon, M. C. Dalakas, Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. Ann. Neurol. 32 (1992), 219–222.
86. P. H. Plotz, M. Dalakas, R. L. Leff, L. A. Love, F. W. Miller, M. E. Cronin, Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis and related disorders. Ann. Intern. Med. 111 (1989), 143–157.
87. I. N. Targoff, Immune mechanisms of myositis. Curr. Opin. Rheumatol. 2 (1990), 882–888.
88. Q. Ge, D. S. Nilasena, C. A. O'Brien, M. B. Frank, I. N. Targoff, Molecular analysis of a major antigenic region of the 240 kD protein of Mi-2 autoantigen. J. Clin. Invest. 96 (1995), 1730–1737.
89. T. Miller, M. T. Al-Lozi, G. Lopate, A. Pestronk, Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J. Neurol. Neurosurg. Psychiatry 73:4 (2002), 420–428.
90. G. J. Hengstman, B. G. van Engelen, W. J. van Venrooij, Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr. Opin. Rheumatol. 16:6 (2004), 692–699.
91. M. C. Dalakas, Understanding the immunopathogenesis of inclusion-body myositis: present and future prospects. Rev. Neurol. (Paris) 158:10 Pt 1 (2002), 948–958.
92. R. Hohlfeld, A. G. Engel, Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann. Neurol. 29 (1991), 498–507.
93. R. Mantegazza, F. Andreette, P. Bernasconi, et al., Analysis of T cell receptor repertoire of muscle infiltrating T lymphocytes in polymyositis. J. Clin. Invest. 91 (1993), 2880–2886.
94. D. Michaelis, N. Goebels, R. Hohlfeld, Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am. J. Pathol. 143:4 (1993), 1142–1149.
95. K. Nagaraju, N. Raben, L. Loeffler, et al., Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc. Natl. Acad. Sci. U. S. A. 97:16 (2000), 9209–9214.
96. P. Englund, E. Lindroos, I. Nennesmo, L. Klareskog, I. E. Lundberg, Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am. J. Pathol. 159:4 (2001), 1263–1273.
97. H. Wiendl, M. Mitsdoerffer, D. Schneider, et al., Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126:Pt 5 (2003) 1026–1035.
98. H. Wiendl, R. Hohlfeld, B. C. Kieseier, Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 26:7 (2005), 373–380.
99. J. L. De Bleecker, A. G. Engel, J. C. Winkelmann, Localization of dystrophin and beta-spectrin in vacuolar myopathies. Am. J. Pathol. 143:4 (1993), 1200–1208.
100. N. Goebels, D. Michaelis, M. Engelhardt, et al., Differential expression of perforin in muscle-inflammatory T cells in polymyositis and dermatomyositis. J. Clin. Invest. 97 (1996), 2905–2910.
101. J. Schmidt, G. Rakocevic, R. Raju, M. C. Dalakas, Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8 + T cell cytotoxicity. Brain 127:Pt 5 (2004), 1182–1190.
102. C. Schneider, R. Gold, M. C. Dalakas, et al., MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibres nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis and inclusion body myositis. J. Neuropathol. Exp. Neurol. 55 (1996), 1205–1209.
103. L. Behrens, A. Bender, M. A. Johnson, R. Hohlfeld, Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 120 (1997), 929–938.
104. K. Nagaraju, L. Casciola-Rosen, A. Rosen, et al., The inhibition of apoptosis in myositis and in normal muscle cells. J. Immunol. 164:10 (2000), 5459–5465.
105. M. Li, M. C. Dalakas, The muscle mitogen-activated protein kinase is altered in sporadic inclusion body myositis. Neurology 54:8 (2000), 1665–1670.
106. T. P. O'Hanlon, M. C. Dalakas, P. H. Plotz, F. W. Miller, Predominant TCR-alpha-beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J. Immunol. 152 (1994), 2569–2576.
107. I. M. Fyhr, A. R. Moslemi, A. A. Mosavi, C. Lindberg, A. Tarkowski, A. Oldfors, Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J. Neuroimmunol. 79 (1997), 185–189.
108. A. Bender, N. Ernst, A. Iglesias, K. Dornmair, H. Wekerle, R. Hohlfeld, T cell receptor in polymyositis: clonal expansion of autoaggressive CD81 T cells. J. Exp. Med. 181 (1995), 1863–1868.
109. O. Benveniste, S. Herson, B. Salomon, et al., Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann. Neurol. 56:6 (2004), 867–872.
110. D. Dimitri, O. Benveniste, O. Dubourg, et al., Shared blood and muscle CD8 + T-cell expansions in inclusion body myositis. Brain 129:Pt 4 (2006), 986–995.
111. M. Salajegheh, G. Rakocevic, R. Raju, A. Shatunov, L. G. Goldfarb, M. C. Dalakas, T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 69:17 (2007), 1672–1679.
112. A. Bender, L. Behrens, A. G. Engel, R. Hohlfeld, T-cell heterogeneity in muscle lesions of inclusion body myositis. J. Neuroimmunol. 84 (1998), 86–91.
113. M. Hofbauer, S. Wiesener, H. Babbe, et al., Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc. Natl. Acad. Sci. U. S. A. 100:7 (2003), 4090–4095.
114. K. Amemiya, R. P. Granger, M. C. Dalakas, Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123 (2000), 2030–2039.
115. K. Müntzing, C. Lindberg, A. R. Moslemi, A. Oldfors, Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand. J. Immunol. 2 (2003), 195–200.
116. R. Hohlfeld, A. G. Engel, L. I. Kunio, M. C. Harper, Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. N. Engl. J. Med. 324 (1991), 877–881.
117. G. Puschke, D. Ruegg, R. Hohlfeld, A. G. Engel, Autoaggressive myocytotoxic T-lymphocytes expressing an unusual gamma delta T cell receptor. J. Exp. Med. 176 (1992), 1785–1789.
118. H. Wiendl, J. Malotka, B. Holzwarth, et al., An autoreactive gamma delta TCR derived from a polymyositis lesion. J. Immunol. 169:1 (2002), 515–521.
119. L. Behrens, M. Kerschensteimer, T. Misgeld, N. Goebels, H. Wekerle, R. Hohlfeld, Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J. Immunol. 161:11 (1998), 5943–5951.
120. K. Murata, M. C. Dalakas, Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies. Am. J. Pathol. 155 (1999), 453–460.
121. E. M. Bradshaw, A. Orihuela, S. L. McArdel, et al., A local antigen-driven humoral response is present in the inflammatory myopathies. J. Immunol. 178:1 (2007), 547–556.
122. M. C. Dalakas, Molecular immunology and genetics of inflammatory muscle diseases. Arch. Neurol. 55 (1998), 1509–1512.
123. B. De Paepe, J. L. De Bleecker, Beta-chemokine receptor expression in idiopathic inflammatory myopathies. Muscle Nerve 31:5 (2005), 621–627.
124. B. De Paepe, K. De Keyzer, J. J. Martin, J. L. De Bleecker, Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol. 109:6 (2005), 576–582.
125. D. Figarella-Branger, J. Pouget, R. Bernard, et al., Limb-girdle muscular dystrophy in a 71-year-old woman with an R27Q mutation in the CAV3 gene. Neurology 61:4 (2003), 562–564.
126. M. Civatte, C. Bartoli, N. Schleinitz, B. Chetaille, J. F. Pellissier, D. Figarella-Branger, Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol. Appl. Neurobiol. 31:1 (2005), 70–79.
127. Y. C. Choi, M. C. Dalakas, Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 54 (2000), 65–71.
128. M. Salajegheh, R. Raju, J. Schmidt, M. C. Dalakas, Upregulation of thrombospondin-1 (TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis. J. Neuroimmunol. 187:1-2 (2007), 166–174.
129. M. C. Dalakas, Sporadic inclusion body myositis – diagnosis, pathogenesis and therapeutic strategies. Nat. Clin. Pract. Neurol. 2:8 (2006b), 437–447.
130. M. C. Dalakas, Toxic and drug-induced myopathies. J. Neurol. Neurosurg. Psychiatry80:8 (2009), 832–838.
131. K. Nagaraju, L. Casciola-Rosen, I. Lundberg, et al., Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52:6 (2005), 1824–1835.
132. I. Ferrer, B. Martín, J. G. Castaño, J. J. Lucas, D. Moreno, M. Olivé, Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J. Neuropathol. Exp. Neurol. 63:5 (2004), 484–498.
133. G. Vattemi, W. K. Engel, J. McFerrin, V. Askanas, Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol. 164:1 (2004), 1–7.
134. V. Askanas, W. K. Engel, Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr. Opin. Rheumatol. 15:6 (2003), 737–744.
135. B. L. Banwell, A. G. Engel, AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 54:5 (2000), 1020–1021.
136. M. C. Dalakas, Interplay between inflammation and degeneration: using inclusion body myositis to study “neuroinflammation”. Ann. Neurol. 64:1 (2008), 1–3.
137. M. C. Dalakas, I. Illa, Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann. Neurol. 37 (1995), 806–810.
138. J. N. Pruitt, 2nd, C. J. Showalter, A. G. Engel, Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann. Neurol. 39:1 (1996), 139–143.
139. Murthet al.
140. S. M. Chou, Inclusion body myositis: a possible chronic persistent mumps myositis?Hum. Pathol. 17 (1986), 765–776.
141. M. C. Dalakas, G. H. Pezeshkpour, M. Gravell, J. L. Sever, Polymyositis in patients with AIDS. J. Am. Med. Assoc. 256 (1986), 2381–2383.
142. H. Nishino, A. G. Engel, B. K. Rima, Inclusion body myositis: the mumps virus hypothesis. Ann. Neurol. 25 (1989), 260–264.
143. M. C. Dalakas, Viral myopathies. In Myology, vol. II, eds. A. G. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 2006), pp. 1419–1437.
144. E. J. Cupler, M. Leon-Monzon, J. Miller, C. Semino-Mora, T. L. Anderson, M. C. DalakasInclusion body myositis in HIV-I and HTLV-I infected patients. Brain 19 (1996), 1887–1893.
145. M. C. Dalakas, W. T. London, M. Gravell, J. L. Sever, Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus. Neurology 36 (1986), 569–572.
146. M. C. Dalakas, G. H. Pezeshkpour, Neuromuscular diseases associated with human immunodeficiency virus infection. Ann. Neurol. 23 Suppl. (1988), 38–48.
147. O. Morgan, C. P. St. Rodgers-Johnson, C. Mora, G. Char, HTLV-1 and polymyositis in Jamaica. Lancet ii (1989), 1184–1187.
148. M. C. Dalakas, G. Rakocevic, A. Shatunov, L. Goldfarb, R. Raju, M. Salajegheh, Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann. Neurol. 61:5 (2007), 466–475.
149. S. Ozden, M. Cochet, J. Mikol, A. Teixeira, A. Gessain, C. Pique, Direct evidence for a chronic CD8 + T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol. 78:19 (2004), 10320–10327.
150. M. C. Dalakas, Advances in the immunobiology and treatment of inflammatory myopathies. Curr. Rheumatol. Rep. 9:4 (2007), 291–297.
151. K. Matsuura, K. Miura, M. Taki, et al., Ocular following responses of monkeys to the competing motions of two sinusoidal gratings. Neurosci. Res. 61:1 (2008), 56–69.
152. I. Illa, A. Nath, M. C. Dalakas, Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann. Neurol. 29 (1991), 474–481.
153. M. Leon-Monzon, I. Illa, M. C. Dalakas, Polymyositis in patients infected with HTLV-1 (the role of the virus in the cause of the disease. Ann. Neurol. 36 (1994), 643–649.
154. M. Leon-Monzon, L. Lamperth, M. C. Dalakas, Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV-polymyositis. Muscle Nerve 16 (1993), 408–413.
155. M. Saito, I. Higuchi, A. Saito, et al., Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J. Infect. Dis. 186:9 (2002), 1231–1241.
156. M. C. Dalakas, I. Illa, G. H. Pezeshkpour, et al., Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 332 (1995), 1098–1105.
157. W. Lewis, M. C. Dalakas, Mitochondrial toxicity of antiviral drugs. Nat. Med. 1:5 (1995), 417–422.
158. H. D. Davies, Flesh-eating disease: a note on necrotizing fasciitis. Can. J. Inf. Dis. 12:3 (2001), 136–140.
159. T. Mimori, Scleroderma-polymyositis overlap syndrome: clinical and seriologic aspects. Int. J. Dermatol. 26 (1987), 419–425.
160. R. A. Foote, S. M. Kimbrough, J. C. Stevens, Lupus myositis. Muscle Nerve 5 (1982), 65.
161. S. P. Ringel, J. Z. Forstot, E. M. Tan, C. Wehling, R. C. Griggs, D. Butcher, Sjögren's syndrome and polymyositis or dermatomyositis. Arch. Neurol. 39 (1982), 157.
162. S. Carpenter, G. Karpati, Granulomatous myopathies. In: Pathology of Skeletal Muscle, eds. S. Carpenter, G. Karpati. (New York: Churchill-Livingstone, 1984), pp. 557–558.
163. K. Le Roux, N. Streichenberger, C. Vial, et al., Granulomatous myositis: a clinical study of thirteen cases. Muscle Nerve 35:2 (2007), 171–177.
164. D. B. Ménard, H. Haddad, J. G. Blain, R. Beaudry, G. Devroede, S. Masse, Granulomatous myositis and myopathy associated with Crohn's disease. N. Engl. J. Med. 295 (1976), 818–819.
165. R. B. Layzer, M. A. Shearn, S. Satya-Murti, Eosinophilic polymyositis. Ann. Neurol. 1 (1977), 65–71.
166. D. B. Simon, S. F. Ringel, R. I. Sufit, Clinical spectrum of fascial inflammation. Muscle Nerve 5 (1982), 525.
167. T. M. File Jr., S. J. Tan, J. R. DiPersio, Group A streptococcal necrotizing fasciitis. Diagnosing and treating the ‘flesh-eating bacteria syndrome’. Cleveland Clin. J. Med. 65 (1998), 241–249.
168. M. A. Gardam, D. E. Low, R. Saginur, M. A. Miller, Group B streptococcal necrotizing fasciitis and streptococcal toxic shock-like syndrome in adults. Arch. Int. Med. 158 (1998), 1704–1708.
169. R. W. Martin, J. Duffy, A. G. Engel, et al., The clinical spectrum of eosinophilia-myalgia syndrome associated with l tryptophan ingestion. Ann. Int. Med. 113 (1990), 124.
170. A. M. Emslie-Smith, A. G. Engel, J. Duffy, C. A. Bowles, Eosinophilia myalgia syndrome: I. Immunocytochemical evidence for a T-cell-mediated immune effector response. Ann. Neurol. 29 (1991), 524–528.
171. M. M. Gherardi, J. C. Ramirez, D. Rodríguez, et al., IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J. Immunol. 162:11 (1999), 6724–6733.
172. R. R. Heffner, V. W. Armbrustmacher, K. M. Earle, Focal myositis. Cancer 40 (1977), 301–306.
173. N. E. Bharucha, J. A. Morgan-Hughes, Chronic focal polymyositis in the adult. J. Neurol. Neurosurg. Psychiatry 44 (1981), 419–425.
174. T. L. Munsat, D. Piper, P. Cancilla, J. Mednick, Inflammatory myopathy with facioscapulohumeral distribution. Neurology 22 (1972), 335–347.
175. A. M. Emslie-Smith, A. G. Engel, Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 41 (1991), 936–939.
176. S. Carpenter, G. Karpati, W. Johnston, E. Shoubridge, M. Gavel, Coexistence of polymyositis (PM) with mitochondrial myopathy (MM). Neurology 42:Suppl. 3 (1992), 388.
177. G. Blume, A. Pestronk, B. Frank, D. R. Johns, Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 120 (1997), 39–45.
178. J. H. Anthony, P. G. Procopis, R. A. Ourvrier, Benign acute childhood myositis. Neurology 29 (1979), 1068–1071.
179. R. L. Ruff, D. Secrist, Viral studies in benign acute childhood myositis. Arch. Neurol. 39 (1982), 261.
180. B. Q. Banker, A. G. Engel, The polymyositis and dermatomyositis syndromes. In: Myology, eds. A. G. Engel, B. Q. Banker. (New York: McGraw Hill, 1986), pp. 1385–1422.
181. C. E. Thompson, Infantile myositis. Dev. Med. Child Neurol. 24 (1982), 307–313.
182. N. Sripathi, G. Karpati, S. Carpenter, A distinctive type of infantile inflammatory myopathy with abnormal myonuclei. J. Neurol. Sci. 136 (1996), 1–2.
183. S. M. Roddy, S. Ashwal, N. Peckham, S. Mortensen, Infantile myositis: a case diagnosed in the neonatal period. Ped. Neurol. 2 (1986), 241.
184. M. Shevell, B. Rosenblatt, C. M. Silver, S. Carpenter, G. Karpati, Congenital inflammatory myopathy. Neurology 40 (1990), 1111–1114.
185. R. K. Olney, R. K. Miller, Inflammatory infiltration in Fukuyama type congenital muscular dystrophy. Muscle Nerve 6 (1983), 75.
186. M. C. Dalakas, Current treatment of the inflammatory myopathies. Curr. Opin. Rheumatol. 6 (1994), 595–601.
187. M. C. Dalakas, Therapeutic approaches in patients with inflammatory myopathies. Semin. Neurol. 23:2 (2003), 199–206.
188. M. Leon-Monzon, M. C. Dalakas, Interleukin-1 (IL-1) is toxic to human muscle. Neurology 44: Suppl. (1994), A132.
189. M. E. Cronin, F. W. Miller, J. E. Hicks, M. Dalakas, P. H. Plotz, The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J. Rheumatol. 16 (1989), 1225–1228.
190. J. Heckmatt, N. Hasson, C. Saunders, et al., Cyclosporin in juvenile dermatomyositis. Lancet i (1989), 1063–1066.
191. J. M. Grau, C. Herrero, J. Casademont, J. Fernandez-Sola, A. Urbano-Marquez, Cyclosporine A as first choice for dermatomyositis. J. Rheumatol. 21 (1994), 381–382.
192. F. W. Miller, S. F. Leitman, M. E. Cronin, et al., Controlled trial of plasma exchange and leukopheresis in patients with polymyositis and dermatomyositis. N. Engl. J. Med. 326 (1992), 1380–1384.
193. J. J. Kelly Jr., H. Madoc-Jones, L. S. Adelman, P. L. Andres, T. L. Munsat, Total body irradiation is not effective in inclusion body myositis. Neurology 36 (1986), 1264–1266.
194. P. Cherin, S. Herson, B. Wechsler, et al., Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients. Am. J. Med. 91 (1991), 162–168.
195. B. Lang, R. M. Laxer, G. Murphy, E. D. Silverman, C. M. Roifman, Treatment of dermatomyositis with intravenous immunoglobulin. Am. J. Med. 91 (1991), 169–172.
196. S. Jan, S. Beretta, M. Moggio, L. Alobbati, G. Pellegrini, High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J. Neurol. Neurosurg. Psychiatry 55 (1992), 60–64.
197. M. C. Dalakas, I. Illa, J. M. Dambrosia, et al., A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329 (1993), 1993–2000.
198. M. C. Dalakas, B. Sonies, B. Koffman, et al., High-dose intravenous immunoglobulin (IVIg) combined with prednisone in the treatment of patients with inclusion-body myositis (IBM): a double blind, randomized controlled trial. Neurology 48 (1997), 332S.
199. M. C. Dalakas, E. A. Sekul, E. J. Cupler, K. Sivakumar, The efficacy of high dose intravenous immunoglobulin (IVIg) in patients with inclusion-body myositis (IBM). Neurology 48 (1997), 712–716.
200. M. C. Dalakas, Intravenous immunoglobulin therapy for neurological diseases. Ann. Intern. Med. 126 (1997), 721–730.
201. T. D. Levine, Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52:2 (2005), 601–607.
202. C. V. Oddis, F. C. Sciurba, K. A. Elmaqd, T. E. Starzl, Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353:9166 (1999), 1762–1763.